<DOC>
	<DOCNO>NCT02900716</DOCNO>
	<brief_summary>This study evaluate safety , antitumor activity preliminary pharmacokinetics investigational drug product , DTRMWXHS-12 , patient chronic lymphocytic leukemia B-cell lymphoma . DTRMWXHS-12 evaluate single agent , combination . This study conduct two part : phase Ia Ib . Both part explore escalate dos DTRMWXHS-12 . The phase Ia study evaluate DTRMWXHS-12 monotherapy . The phase Ib study evaluate DTRMWXHS-12 combination .</brief_summary>
	<brief_title>Safety Study BTK Inhibitor , DTRMWXHS-12 , Used Singly Combination , CLL B-cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients diagnosis chronic lymphocytic leukemia ( CLL ) Bcell neoplasm include small lymphocytic lymphoma ( SLL ) , mantle cell lymphoma ( MCL ) , marginal zone lymphoma ( MZL ) follicular Bcell nonHodgkin 's lymphoma ( FL ) available approved therapy . Age &gt; 18 year . Life expectancy great 12 week . Patients must ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 . Patients must provide write informed consent . Ability swallow retain capsule . Absence uncontrolled intercurrent illness , include uncontrolled infection , cardiac condition , organ dysfunction . Women childbearing potential must negative serum urine pregnancy test . Women childbearing potential must agree use 2 reliable method contraception begin 4 week prior initiation treatment , therapy , least 4 week last drug administration . Men must agree use latex synthetic condom sexual contact pregnant female female become pregnant , duration study least 4 week last drug administration , even undergone successful vasectomy . Received previous chemotherapy , immunotherapy , radiotherapy investigational therapy within 21 day 5 halflives target therapy prior study entry . Patients active infection require intravenous ( IV ) antibiotic/antiviral therapy eligible entry onto study resolution infection ; patient prophylactic antibiotic , antifungal antiviral acceptable Pregnant lactating individual . Impaired hepatic renal function demonstrate follow laboratory value : 1 . AST ALT &gt; 2.5 x ULN 2 . Total bilirubin &gt; 1.5 x ULN ( Patients history Gilbert 's syndrome may participate total bilirubin less equal 1.5 x ULN AST/ALT alkaline phosphatase meet protocolspecified level eligibility ) 3 . Alkaline phosphatase &gt; 2.5 x ULN 4 . Glomerular filtration rate ( GFR ) &lt; 50 mL/min , assess use standard methodology investigate center ( i.e . CockroftGault ) , serum creatinine &gt; 1.5 x ULN INR &gt; 1.5 evidence impair hepatic synthesis function . Persisting ( &gt; 8 week ) severe pancytopenia due hematologic disorder due previous therapy rather disease ( ANC &lt; 0.5 x 109/L platelet &lt; 30 x 109/L ) confirm via bone marrow biopsy , part normal clinical care , prior sign consent . Previous allogeneic bone marrow transplant restrict , unless evidence acute chronic graft versus host disease . CNS involvement malignancy . Current malignancy another type , exception adequately treat situ cervical cancer basal cell skin cancer , squamous cell carcinoma skin malignancy evidence disease 2 year . Known history HIV , HBV HCV infection . Documented known bleeding disorder . Requirement anticoagulation treatment increase INR aPTT normal range ( low molecular weight heparin heparin line flush allow ) . Patient receive azole . Patients significant cardiovascular disease condition , include : Myocardial infarction within 6 month study entry NYHA Class III IV heart failure , reduce LVEF &lt; 50 % Uncontrolled dysrhythmias poorly control angina . History serious ventricular arrhythmia ( VT VF , ≥ 3 beat row ) and/or risk factor ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Baseline prolongation QT/QTc interval ( repeat demonstration QTc ≥ 450 msec men 470 msec woman , LVEF ≤ 40 % MUGA ECHO ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>